Fig. 1
From: Identification of a class of potent USP25/28 inhibitors with broad-spectrum anti-cancer activity
Identification of USP28 inhibitors. a The chemical structures of CT1073 and CT1113. b Western blotting analysis of the indicated proteins in the cells treated with 500 nM CT1073 or CT1113 for 24 h. c The effect of CT1113 in a pancreatic cancer CDX model generated by inoculating SW1990 cells into Balb/c nude mice (n = 8 mice per group). The photographs of the tumors are presented. d Western blotting analysis of the tumor samples shown in c. e Hematoxylin and eosin (H&E) staining and immunohistochemical staining of the small intestines from the vehicle control and CT1113 treated animals (n = 3 mice per group). f. Quantitation of BrdU incorporation. The BrdU positive cells in the intestinal crypts (e) were counted and plotted. Student’s t-test: n.s. indicates no significant difference. g Western blotting analysis of USP28 and c-MYC levels in the intestine from control and CT1113-treated mice. The numbers are band intensities of USP28 or c-MYC relative to GAPDH which were further normalized against sample 1 in the control group
